Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Thermo Fisher Scientific prices €2.1B euro-denominated senior notes offering - MSN
Thermo Fisher Scientific prices €2.1B euro-denominated senior notes offering MSN
Thermo Fisher Scientific Subsidiary Prices EUR 2.1 Bln Senior Notes Offering - Nasdaq
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX M...
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes - MarketScreener
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes MarketScreener
Thermo Fisher Scientific sets up 2 facilities in Hyd - BusinessLine
Thermo Fisher Scientific sets up 2 facilities in Hyd BusinessLine
Fitch Rates Thermo Fisher Scientific (Finance I) B.V.'s Senior Euro Notes 'A-' - TradingView
Fitch Rates Thermo Fisher Scientific (Finance I) B.V.'s Senior Euro Notes 'A-' TradingView
Thermo Fisher Scientific (TMO): Assessing Valuation After FDA Wins Expand Cancer and Diagnostic Offerings - simplywall.st
Thermo Fisher Scientific (TMO): Assessing Valuation After FDA Wins Expand Cancer and Diagnostic Offerings simplywall.st
Thermo Fisher Scientific Stock Prediction: Where Analysts See the Stock Going by 2027 - TIKR.com
Thermo Fisher Scientific (NYSE: TMO) has remained one of the most consistent companies in the life sciences sector. Even with slower bioprocessing activity and more cau...
Thermo Fisher Scientific: Assessing Value After Diagnostics Acquisition and Recent Share Price Gains - simplywall.st
Thermo Fisher Scientific: Assessing Value After Diagnostics Acquisition and Recent Share Price Gains simplywall.st
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer - Business Wire
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Sma...